Porcine reproductive and respiratory syndrome virus (PRRSV) is the pathogen of the porcine reproductive and respiratory syndrome, which is one of the most economically devastating diseases of the swine industry. However, whether the inactivated vaccine and modified live attenuated vaccines are effective in disease control is still controversial. Although several groups developed PRRSV virus-like particles (VLPs) as a vaccine against PRRSV, all these VLP-based vaccines targeted PRRSV-2, but not PRRSV-1 or both. Therefore, it is urgent to produce VLPs against PRRSV-1. In this study, we rescued recombinant baculovirus expressing GP5 and M proteins of PRRSV-1 through the Bac-to-Bac® baculovirus expression system. Thereafter, PRRSV VLP was obtained efficiently in the recombinant baculovirus-infected High Five insect cells. Moreover, the PRRSV VLP and PRRSV VLP+A5 could efficiently trigger specific humoral immune responses and B cellular immune responses through intranasal immunization. The combination of PRRSV VLP and A5 adjuvant could improve the level of the immune response. The PRRSV-1 VLPs generated in this study have greater potential for vaccine development to control PRRSV-1 infection.
Get full access to this article
View all access options for this article.
References
1.
ArrudaAG, TousignantS, SanhuezaJ, et al.Aerosol detection and transmission of porcine reproductive and respiratory syndrome virus (PRRSV): what is the evidence, and what are the knowledge gaps?. Viruses, 2019; 11:712.
2.
BinjawadagiB, LakshmanappaYS, LongchaoZ, et al.Development of a porcine reproductive and respiratory syndrome virus-like-particle-based vaccine and evaluation of its immunogenicity in pigs. Arch Virol, 2016; 161:1579–1589.
3.
CaoY, OuyangH, ZhangM, et al.Analysis of molecular variation in porcine reproductive and respiratory syndrome virus in China between 2007 and 2012. Virol Sin, 2014; 29:183–188.
4.
CharerntantanakulW. Porcine reproductive and respiratory syndrome virus vaccines: immunogenicity, efficacy and safety aspects. World J Virol, 2012; 1:23–30.
5.
ChenN, CaoZ, YuX, et al.Emergence of novel European genotype porcine reproductive and respiratory syndrome virus in mainland China. J Gen Virol, 2011; 92:880–892.
6.
DíazI, DarwichL, PappaterraG, et al.Different European-type vaccines against porcine reproductive and respiratory syndrome virus have different immunological properties and confer different protection to pigs. Virology, 2006; 351:249–259.
7.
DiazI, PujolsJ, GangesL, et al.In silico prediction and ex vivo evaluation of potential T-cell epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I (European) of porcine reproductive and respiratory syndrome virus. Vaccine, 2009; 27:5603–5611.
8.
DuT, NanY, XiaoS, et al.Antiviral strategies against PRRSV infection. Trends Microbiol, 2017; 25:968–979.
9.
EclercyJ, RensonP, LebretA, et al.A field recombinant strain derived from two type 1 porcine reproductive and respiratory syndrome virus (PRRSV-1) modified live vaccines shows increased viremia and transmission in SPF pigs. Viruses, 2019; 11:296.
10.
Garcia DuranM, CostaS, SarrasecaJ, et al.Generation of porcine reproductive and respiratory syndrome (PRRS) virus-like-particles (VLPs) with different protein composition. J Virol Methods, 2016; 236:77–86.
11.
HillBD, ZakA, KheraE, et al.Engineering virus-like particles for antigen and drug delivery. Curr Protein Pept Sci, 2018; 19:112–127.
12.
KappesMA, and FaabergKS. PRRSV structure, replication and recombination: origin of phenotype and genotype diversity. Virology, 2015; 479–480:475–486.
13.
LiB, GaoS, ZhouT, et al.Complete genome sequence of European genotype porcine reproductive and respiratory syndrome virus strain LNEU12 in Northern China. Genome Announc, 2014; 2:e00957–14.
14.
LinB, LiuK, WangW, et al.Expression and bioactivity of human alpha-fetoprotein in a Bac-to-Bac system. Biosci Rep, 2017; 37:BSR20160161.
15.
LiuC, DuS, LiC, et al.Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization. Sci China Life Sci, 2013; 56:531–540.
16.
LiuX, OuyangT, OuyangH, et al.Human cells are permissive for the productive infection of porcine circovirus type 2 in vitro. Sci Rep, 2019; 9:5638.
17.
LuY, GillamF, CaoQM, et al.Hepatitis B core antigen-based vaccine demonstrates cross-neutralization against heterologous North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-2) strains. J Virol Methods, 2020; 285:113945.
18.
LunneyJK, BenfieldDA, and RowlandRR. Porcine reproductive and respiratory syndrome virus: an update on an emerging and re-emerging viral disease of swine. Virus Res, 2010; 154:1–6.
19.
LunneyJK, FangY, LadinigA, et al.Porcine reproductive and respiratory syndrome virus (PRRSV): pathogenesis and Interaction with the immune system. Annu Rev Anim Biosci, 2016; 4:129–154.
20.
MengXJ. Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development. Vet Microbiol, 2000; 74:309–329.
21.
MohsenMO, ZhaL, Cabral-MirandaG, et al.Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol, 2017; 34:123–132.
22.
Montaner-TarbesS, Del PortilloHA, MontoyaM, et al.Key gaps in the knowledge of the porcine respiratory reproductive syndrome virus (PRRSV). Front Vet Sci, 2019; 6:38.
23.
NamH-M, ChaeK-S, SongY-J, et al.Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus. Arch Virol, 2013; 158:1275–1285.
24.
NanY, WuC, GuG, et al.Improved vaccine against PRRSV: current progress and future perspective. Front Microbiol, 2017; 8:1635.
25.
OngHK, TanWS, and HoKL. Virus like particles as a platform for cancer vaccine development. PeerJ, 2017; 5:e4053.
26.
OuyangT, ZhangX, LiuX, et al.Co-infection of swine with porcine circovirus type 2 and other swine viruses. Viruses, 2019; 11:185.
27.
Rascon-CasteloE, Burgara-EstrellaA, Resendiz-SandovalM, et al.Immune response of multiparous hyper-immunized sows against peptides from non-structural and structural proteins of PRRSV. Vaccines (Basel), 2015; 3:973–987.
28.
ShangH, GarretsonTA, KumarCMS, et al.Improved pFastBac donor plasmid vectors for higher protein production using the Bac-to-Bac(R) baculovirus expression vector system. J Biotechnol, 2017; 255:37–46.
29.
StadejekT, StankeviciusA, MurtaughMP, et al.Molecular evolution of PRRSV in Europe: current state of play. Vet Microbiol, 2013; 165:21–28.
30.
StankeviciusA, BuitkuvieneJ, SutkieneV, et al.Detection and molecular characterization of porcine reproductive and respiratory syndrome virus in Lithuanian wild boar populations. Acta Veter Scand, 2016; 58:51.
31.
Stolt-BergnerP, BendaC, BergbredeT, et al.Baculovirus-driven protein expression in insect cells: a benchmarking study. J Struct Biol, 2018; 203:71–80.
32.
SuF, XuL, XueY, et al.Th1-biased immunoadjuvant effect of the recombinant B subunit of an Escherichia coli heat-labile enterotoxin on an inactivated porcine reproductive and respiratory syndrome virus antigen via intranasal immunization in mice. J Vet Med Sci, 2019; 81:1475–1484.
33.
Van BreedamW, CostersS, VanheeM, et al.Porcine reproductive and respiratory syndrome virus (PRRSV)-specific mAbs: supporting diagnostics and providing new insights into the antigenic properties of the virus. Vet Immunol Immunopathol, 2011; 141:246–257.
34.
WangR, XiaoY, OpriessnigT, et al.Enhancing neutralizing antibody production by an interferon-inducing porcine reproductive and respiratory syndrome virus strain. Vaccine, 2013; 31:5537–5543.
35.
WangS, FangL, FanH, et al.Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine, 2007; 25:8220–8227.
36.
WangW, ChenX, XueC, et al.Production and immunogenicity of chimeric virus-like particles containing porcine reproductive and respiratory syndrome virus GP5 protein. Vaccine, 2012; 30:7072–7077.
37.
WildeM, KlausbergerM, PalmbergerD, et al.Tnao38, high five and Sf9—evaluation of host-virus interactions in three different insect cell lines: baculovirus production and recombinant protein expression. Biotechnol Lett, 2014; 36:743–749.
38.
XueC, WangW, LiuQ, et al.Chimeric influenza-virus-like particles containing the porcine reproductive and respiratory syndrome virus GP5 protein and the influenza virus HA and M1 proteins. Arch Virol, 2014; 159:3043–3051.
39.
ZhouF, ZhaoJ, ChenL, et al.Complete genome sequence of a novel porcine reproductive and respiratory syndrome virus that emerged in China. Genome Announc, 2015; 3:e00702–15.
40.
ZhuB, HeT, GaoX, et al.Evaluation and characteristics of immunological adjuvant activity of purified fraction of Albizia julibrissin saponins. Immunol Invest, 2019; 48:283–302.
41.
ZuckermannFA, GarciaEA, LuqueID, et al.Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. Vet Microbiol, 2007; 123:69.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
